A Key Therapeutic Breakthrough Against T315I-Mutant CML

Ponatinib is definitively classified as a third-generation BCR-ABL tyrosine kinase inhibitor (TKI). Its groundbreaking feature is the proven efficacy against virtually all known BCR-ABL resistance mutations, including the “gatekeeper” T315I mutation, against which first- (e.g., imatinib) and second-generation (e.g., nilotinib, dasatinib) TKIs are ineffective.

The molecular design of ponatinib ingeniously targets the ATP-binding pocket of the BCR-ABL fusion protein. Its unique acetylene-linked purine scaffold enables stable interaction with the isoleucine side chain formed after the T315I mutation, thereby overcoming resistance. This also makes it a multi-kinase inhibitor, though its inhibition of receptors like VEGFR is associated with specific vascular toxicity risks.

For chronic-phase CML patients harboring the T315I mutation, ponatinib has transformed the treatment paradigm, rescuing them from a previously poor prognosis, and is recommended as the preferred therapy in international clinical guidelines. Study data demonstrate that ponatinib induces high rates of cytogenetic and molecular responses in this patient population.

In clinical practice, ponatinib is primarily indicated for CML patients who have failed at least two prior TKIs or who have confirmed T315I mutation. Treatment requires careful assessment and monitoring for risks of arterial occlusive events. Strategies employing a lower starting dose (e.g., 15mg or 30mg once daily) with subsequent dose reduction upon achieving a deep response have been shown to maintain efficacy while significantly reducing vascular event risks.

Although newer agents targeting different sites (e.g., the myristoyl pocket) have emerged, ponatinib remains an indispensable cornerstone therapy for the T315I mutation due to its proven efficacy. It continues to play a critical role as a “last line” of defense in the treatment sequence for resistant CML.